buchspektrum Internet-Buchhandlung

Neuerscheinungen 2010

Stand: 2020-01-07
Schnellsuche
ISBN/Stichwort/Autor
Herderstraße 10
10625 Berlin
Tel.: 030 315 714 16
Fax 030 315 714 14
info@buchspektrum.de

Meron Mengistu

Flow-Induced Changes in Endothelial Cell Micro-Mechanical Properties


Application of the Oscillating Optical Tweezers Methodology to Study Mechanosensing Events
2010. 124 S.
Verlag/Jahr: VDM VERLAG DR. MÜLLER 2010
ISBN: 3-639-29671-0 (3639296710)
Neue ISBN: 978-3-639-29671-6 (9783639296716)

Preis und Lieferzeit: Bitte klicken


Studying mechanical properties of cells is becoming increasingly important in understanding how they behave, and interact with their environment. Endothelial cells (ECs) have the capability of sensing and distinguishing between low and high fluid shear stress (FSS) conditions in the vasculature (mechanosensing), leading to preferential localization of atherosclerotic lesions in regions of arterial curvatures where blood flow changes direction and the FSS is physiologically lower. In this book, the oscillating optical tweezers (OOT) methodology was developed as a tool to study micro-mechanical properties of ECs, and used to examine mechanical changes in the vicinity of two mechanosensors, integrin and PECAM, as a response to FSS. FSS-induced structural changes in the vicinity of these mechanosensors were also visualized using confocal microscopy, where actin filament association with integrin and PECAM mechanosensors was examined using the DuolinkTM Proximity Ligation Assay. These studies provided an insight on FSS-induced mechanical and structural changes in the vicinity of integrin and PECAM mechanosensors that could lead to a better understanding of mechanosensing events in ECs.
Meron Mengistu obtained her Ph.D. in Molecular Biology from Lehigh University in Bethlehem, Pennsylvania. Her research interests encompass the understanding of structural and mechanical changes in cells, and the signaling events that control these changes in diseases such as atherosclerosis, HIV/AIDS, and cancer.